http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 04:43:01 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Rhythm+Pharmaceuticals+%28RYTM%29+Reiterated+at+Market+Outperform+by+Citizens+/26594423.html <p>Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $155.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).</p><p>The analyst commented, " We continue to like setmelanotide’s expansion into Prader-Willi Syndrome (PWS), supported by early evidence that MC4R agonism can deliver a differentiated clinical profile— most notably with meaningful BMI reductions, which has not been demonstrated with the only FDA-approved therapy, Vykat XR. While comparisons are limited by small sample size, open-label design, and cross-trial differences, the early hyperphagia signal appears at least comparable to Vykat XR, with the added benefit of weight loss. RYTM shares climbed to >$115 when the http://www.streetinsider.com/Analyst+Comments/Rhythm+Pharmaceuticals+%28RYTM%29+Reiterated+at+Market+Outperform+by+Citizens+/26594423.html Wed, 03 Jun 2026 04:43:01 -0400 RYTM http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++RHYTHM+PHARMACEUTICALS%2C++++++++++++++/26575190.html si-local-file:///var/storage/secattach/20260529/26575190.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++RHYTHM+PHARMACEUTICALS%2C++++++++++++++/26575190.html Fri, 29 May 2026 16:10:00 -0400 O.21655562 RYTM http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++RHYTHM+PHARMACEUTICALS%2C++++++++++++++/26575190.html si-local-file:///var/storage/secattach/20260529/26575190.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++RHYTHM+PHARMACEUTICALS%2C++++++++++++++/26575190.html Fri, 29 May 2026 16:10:00 -0400 O.21655562 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Seven+Abstracts+Accepted+for+Presentation+at+ENDO+2026/26570847.html <p align="left">BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago.</p> <p align="left">Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine, will present results from an ongoing Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), evaluating higher doses and longer treatment duration. The http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Seven+Abstracts+Accepted+for+Presentation+at+ENDO+2026/26570847.html Fri, 29 May 2026 08:00:00 -0400 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Seven+Abstracts+Accepted+for+Presentation+at+ENDO+2026/26570847.html <p align="left">BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago.</p> <p align="left">Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine, will present results from an ongoing Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), evaluating higher doses and longer treatment duration. The http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Seven+Abstracts+Accepted+for+Presentation+at+ENDO+2026/26570847.html Fri, 29 May 2026 08:00:00 -0400 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Press+Releases/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html <p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IGVJHOyFHzGz4XDOjIx1OFAY8LepN5Jw2YKqvqtZDzIsBf56LQfNWkXVrwQvtD3Pi5t7XaYV0rwTNlALcisZeDOe7KT6lFSmhUCanWIi-pYToiIgQNJRYK51EsGuYJJCzeCAgpYw_0r0k2XuFiZUQgCg7DuiTXSUOvezDFDh5GY-KCfrZIGj3_qMe3yI4c2LYPa8xLxKjaBJh22XAHS3_w==" rel="nofollow" target="_blank"><em>American Journal of Medical Genetics</em></a>.</p> <p align="left">This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of international experts and http://www.streetinsider.com/Globe+Newswire/Rhythm+Pharmaceuticals+Announces+Publication+of+New+Bardet-Biedl+Syndrome+Diagnostic+Algorithm+in+the+American+Journal+of+Medical+Genetics/26561294.html Thu, 28 May 2026 08:00:00 -0400 A.06822034 A.08298941 A.31293549 A.39807895 A.60012004 O.00573636 O.01304637 O.12449932 O.20026344 O.21655562 O.49194046 RYTM